RecentRCT

DAPA ACT HF-TIMI 68

Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.

Circulation, 2025 · Multicenter randomized trial

Population: 2,401 hospitalized acute-HF adults after initial stabilization
Intervention: Dapagliflozin 10 mg daily
Comparator: Placebo
Primary outcome: Worsening HF or cardiovascular death through two months
Result: 10.9% versus 12.7%, HR 0.86 (95% CI 0.68–1.08), P=.20.

What the trial found

10.9% versus 12.7%, HR 0.86 (95% CI 0.68–1.08), P=.20.

Clinical interpretation

No significant primary benefit; pooled SGLT2 evidence in the paper is separate from the neutral individual trial. Not shock/SCAPE rescue.

Moderate certainty

Clinical Context & Relevant Topics (2)

Disease Reference

Acute Heart Failure & Cardiogenic Congestion

Hemodynamic phenotypes (SCAPE vs ADHF vs Cardiogenic Shock), non-invasive positive pressure ventilation, high-dose vasodilator algorithms, loop diuretics, and sequential nephron blockade.

View Topic Context →

Acute Cardiogenic Pulmonary Edema & SCAPE

Hydrostatic pulmonary edema physiology, SCAPE vs decompensated HF vs cardiogenic shock, NIV, titrated vasodilators when hypertensive, diuresis, and sequential nephron blockade.

View Topic Context →